Instrument Inactif

Communiqués COSMO Pharmaceuticals SA Swiss Exchange

Actions

LU1202320294

Produits pharmaceutiques

Cours en clôture Swiss Exchange
- ^CHF	-

14/08	Cosmo toilette son codage sur SIX pour refléter son côté medtech	AW
14/08	Cosmo change de ticker à la Bourse suisse	AW

Communiqués

14/08	Cosmo Announces SIX Ticker Symbol Change to "CMHC"	NE
23/07	Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance	NE
01/07	Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026	NE
15/06	Cosmo Welcomes the Launches of Winlevi(R) in Austria and Germany	NE
11/06	Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark	NE
18/05	Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program	NE
18/05	Cosmo N : Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program (EN)	PU
15/04	Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant	NE
15/04	Cosmo Pharmaceuticals N : Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which Are Statistically Significant (EN)	PU
10/04	Voting Results of Cosmo's 2026 AGM	NE
10/04	Cosmo Pharmaceuticals N : Voting results of Cosmo’s 2026 AGM (EN)	PU
10/04	Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Voting Results	PU
10/04	Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Distribution Information	PU
10/04	Cosmo Pharmaceuticals N : AGM – 10 April 2026 – Minutes	PU
16/03	Cosmo Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026	NE
16/03	Cosmo Pharmaceuticals N : Highlights Leadership in Real Time Medical AI at NVIDIA GTC 2026 (EN)	PU
12/03	Cosmo Presents Agenda for AGM 2026	NE
09/03	Cosmo Pharmaceuticals N : Achieves €104.2M Revenue and €9.5M EBITDA in 2025; Proposes €2.10 Dividend; Establishes 2026 Growth Framework (EN)	PU
09/03	Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework	NE
09/03	Cosmo Pharmaceuticals N : ESG Report 2025	PU
05/03	Cosmo Pharmaceuticals N : Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett’s Esophagus (EN)	PU
05/03	Cosmo Announces Strategic R&D Collaboration to Advance AI-Based Detection of Early Neoplasia in Barrett's Esophagus	NE
18/02	Cosmo to Participate in Upcoming Investor Conferences	NE
18/02	Cosmo Pharmaceuticals N : to participate in Upcoming Investor Conferences (EN)	PU
18/02	Cosmo Pharmaceuticals N : to participate in Upcoming Investor Conferences (DE)	PU